Find Out What

Can Mean for Your Patients1-3

Mozobil + granulocyte-colony stimulating factor (G-CSF) has been shown to improve mobilization compared to G-CSF alone in patients with non-Hodgkin’s lymphoma (NHL) and multiple myeloma (MM).

Get the Details

About Mozobil

Mozobil is indicated in combination with G-CSF to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with NHL and MM.1

Mozobil is a first in class CXCR4 receptor antagonist.1

more about mozobil

Dosing and Administration

Begin treatment with Mozobil after the patient has received G-CSF once daily for 4 days. Administer Mozobil approximately 11 hours before initiation of each apheresis while continuing daily G-CSF administration. Mozobil administration can be up to 4 consecutive days.1

More about dosing and administration

Sanofi Genzyme Is Committed to Helping Patients

The Sanofi Patient Connection (SPC) provider portal allows you to enroll and manage your patients in the suite of access services. The secure web-based portal is available 24 hours a day, 7 days a week.

  • Reimbursement Connection: assistance with insurance coverage
  • Patient Assistance Connection: eligibility for no-cost treatment
  • Resource Connection: identify available resources and support

patient support


  1. Mozobil [prescribing information]. Cambridge, MA: Genzyme Corporation; 2017.
  2. DiPersio JF, Micallef IN, Stiff PJ, et al. Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin’s lymphoma. J Clin Oncol. 2009;27(28):4767-4773.
  3. DiPersio JF, Stadtmauer EA, Nademanee A, et al; for the 3102 Investigators. Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood. 2009;113(23):5720-5726.